

110
7-5-00
7-5-00

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

6/11/00
Date

Gina N. Shishima
Gina N. Shishima



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Susan Lindquist

Serial No.: 09/207,649

Filed: December 8, 1998

For: METHODS FOR IDENTIFYING
FACTORS THAT CONTROL THE
FOLDING OF AMYLOID PROTEINS OF
DIVERSE ORIGIN

Group Art Unit: 1644

Examiner: Turner, S.

Atty. Dkt. No.: ARCD:278/WIM

**AMENDMENT UNDER 37 C.F.R. § 1.116;
RESPONSE TO FINAL OFFICE ACTION DATED FEBRUARY 1, 2000**

BOX AF

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

*Don't
forget
7-5-00*

Applicant respectfully requests that the following amendments be entered in the captioned patent application in accordance with 37 C.F.R. § 1.116. Applicant submits the foregoing amendments to place the case in even better condition for allowance or appeal.

This paper is submitted in response to the final Office Action dated February 1, 2000 for which the three-month date for response was May 1, 2000.

A request for a one-month extension of time to respond is included herewith along with the required fee. This one-month extension will bring the due date to June 1, 2000, which is within the six-month statutory period. Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Assistant Commissioner is authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/ARCD:278/WIM.

Reconsideration of the application in view of the following amendments and remarks is respectfully requested.

AMENDMENT

Please cancel claims 22-36 without prejudice or disclaimer.

Please enter the following amendments to the claims:

1. (Amended twice) A method of identifying a candidate substance that inhibits the aggregation of a mammalian aggregate-prone amyloid protein, comprising:

(a) contacting a yeast cell that expresses an aggregate-prone amyloid protein *(a mammalian)* comprising a mammalian aggregate-prone amyloid peptide [protein] with said candidate substance under conditions effective to allow aggregated amyloid formation; and

(b) determining the ability of said candidate substance to inhibit the aggregation of the [mammalian] aggregate-prone amyloid protein.

4. (Amended twice) The method of claim 1, wherein the [mammalian] aggregate-prone amyloid protein is a chimeric protein.

Please add the following claims: